CD19 and lymphoma: CD19 targeting CAR T cells with both a TRAC and B2M gene disrupted by CRISPR/Cas9 are currently under clinical investigation for the treatment of relapsed or refractory CD19+ leukaemia and lymphoma (NCT03166878).